ArticleInnovations in clinical neuroscience2014
Anosognosia in schizophrenia: hidden in plain sight.
Article in Innovations in clinical neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- The Effects of Bi-Anodal tDCS Over the Prefrontal Cortex Regions With Extracephalic Reference Placement on Insight Levels and Cardio-Respiratory and Autonomic Functions in Schizophrenia Patients and Exploratory Biomarker Analyses for Treatment Response.The international journal of neuropsychopharmacology · 2021Trial
- Clinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms.Schizophrenia research. Cognition · 2027Article
- Review
- Frontal Disorders and Consciousness: A Review.Current neurology and neuroscience reports · 2025Review
- Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities.Schizophrenia bulletin · 2025Review
- Forensic assertive community treatment: an emerging best practice.CNS spectrums · 2025Review
- Anosognosia in schizophrenia.CNS spectrums · 2024Review
- Implicit Selective Attention: The Role of the Mesencephalic-basal Ganglia System.Current neuropharmacology · 2024Review
- Receptor-Independent Therapies for Forensic Detainees with Schizophrenia-Dementia Comorbidity.International journal of molecular sciences · 2023Article
- Six Decades of Dopamine Hypothesis: Is Aryl Hydrocarbon Receptor the New D2?Reports (MDPI) · 2023Review
- Article
- Anosognosia in hoarding disorder is predicted by alterations in cognitive and inhibitory control.Scientific reports · 2022Article
- Subjective Cognitive Complaints in Unaffected First-Degree Relatives of Schizophrenia Patients: Relation to Cognitive Performance, Psychotic Experiences, and Social Functioning.Indian journal of psychological medicine · 2022Article
- Subjective cognitive complaints and relations to objective cognitive performance among Lebanese patients with schizophrenia.BMC psychiatry · 2021Article
- Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity.NPJ schizophrenia · 2019Article
- Involvement of the Cingulate Cortex in Anosognosia: A Multimodal Neuroimaging Study in Alzheimer's Disease Patients.Journal of Alzheimer's disease : JAD · 2018Article
- Article
- Observational
- Insight and Psychosis.Indian journal of psychological medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePoor insight is a cardinal symptom of schizophrenia that, while not universally and uniformly expressed in all patients, is among the most common of its manifestations. Available neurobiological and neurocognitive evidence linking the phenomenon to core pathophysiology of schizophrenia justifies extension of the anosognosia construct to schizophrenia-related insight deficits. Poor insight is a core attribute of schizophrenia, occurring in 57 to 98 percent of patients. Insight is an important outcome predictor, associated with treatment adherence, relapse frequency, symptom remission, psychosocial functioning, vocational attainment, and risk of violence toward self or others. Combined findings lend urgency to the importance of reducing psychotic relapse. This can only be achieved in the majority of patients with consistent medication adherence- something that is often exceedingly difficult in patients lacking belief in the fact of their illness. This article examines whether anosognosia, the unawareness of deficit or illness, should apply to our understanding of insight deficits in patients with schizophrenia. Although research in the field is limited at this time, there is hope that anosognosia as a symptom of schizophrenia will become a focus of further research and a critically important therapeutic target amenable to treatment.
designThis article is a literature review and conceptualization.
conclusionLimited research in the field gives cause for hope that anosognosia as a symptom of schizophrenia will become a critically important therapeutic target that is amendable to treatment.
Indexed as
Identifiers
25152841PMC4140620W1862162680What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.